Trump to impose 100% tariff on China starting November 1
CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR) will present 48-week clinical data from a Phase 3 study of telitacicept in adults with generalized myasthenia gravis at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, according to a company press release.
The study, conducted in China and sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX:9995, SHA:688331), will be featured as an oral presentation on October 29 at the conference in San Francisco. The announcement comes as Vor’s stock has shown significant momentum, with InvestingPro reporting an impressive 82% return over the past six months, despite recent volatility.
Telitacicept is a recombinant fusion protein designed to treat autoimmune diseases by inhibiting two cytokines involved in B cell and plasma cell survival. In the previously reported results from this Phase 3 trial, telitacicept demonstrated a placebo-adjusted 4.83-point improvement in the Myasthenia Gravis Activities of Daily Living scale at 24 weeks.
The drug has already received regulatory approval in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis. A global Phase 3 clinical trial in generalized myasthenia gravis is currently underway across multiple regions to support potential approval in the United States, Europe, and Japan.
Generalized myasthenia gravis is a rare autoimmune neuromuscular disorder that causes muscle weakness affecting mobility, vision, swallowing, and breathing. Approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan live with the condition. While analysts have set price targets ranging from $0.30 to $3.00 for Vor Bio, investors seeking deeper insights into the company’s financial health and growth prospects can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
In other recent news, Vor Biopharma announced a 1-for-20 reverse stock split of its common stock, effective Thursday. This decision, approved by stockholders at a special meeting, will consolidate every 20 shares into one, with no change to the par value per share. Additionally, shareholders entitled to fractional shares will receive a cash payment instead. Vor Biopharma also revealed changes to its board of directors, with the resignations of Joshua Resnick, M.D., Matthew Patterson, and David Lubner, none of which were due to disagreements with the company. In other developments, Vor Biopharma’s collaborator, RemeGen Co., Ltd, successfully met the primary endpoint in a Phase 3 clinical study for telitacicept in adults with IgA nephropathy. The study demonstrated a 55% reduction in the 24-hour urine protein-to-creatinine ratio at 39 weeks compared to placebo. Furthermore, Vor Biopharma’s shareholders approved an amendment to the 2021 Equity Incentive Plan, increasing the share reserve by 25 million and reducing the annual automatic increase from 5% to 4% of outstanding shares through 2035.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.